Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DM919 + pembrolizumab
- Development stage
- Phase 1
- Lead developer
- D2M Biotherapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**DM919 + pembrolizumab** is an investigational combination therapy for advanced solid tumors, currently in Phase 1 clinical trials. DM919 is a humanized monoclonal antibody targeting MICA/B proteins, which are stress-induced ligands highly expressed by cancer cells. DM919 inhibits the shedding of MICA/B from tumor cells, restoring and enhancing NKG2D-dependent activation of T and NK cells to promote anti-tumor immune response. Pembrolizumab is a monoclonal antibody that blocks the PD-1 receptor on T cells, preventing tumor-mediated immune evasion and further amplifying the immune response. The combination aims to synergize both innate (via DM919) and adaptive (via pembrolizumab) immune responses, potentially overcoming resistance in tumors with low MHC-I expression. The combination is being investigated to establish safety, tolerability, pharmacokinetic/pharmacodynamic profiles, and preliminary efficacy in patients with advanced or metastatic solid tumors[1][2][3][4][6].
- Other names
- DM919 + pembrolizumab
02
Targets
MICA (Major histocompatibility complex class I-related protein A)MICB (Major histocompatibility complex class i-related protein B)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on DM919 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DM919 + pembrolizumab.